Probiotic Lactobacillus reuteri Prevents Postantibiotic Bone Loss by Reducing Intestinal Dysbiosis and Preventing Barrier Disruption

Antibiotic treatment, commonly prescribed for bacterial infections, depletes and subsequently causes long-term alterations in intestinal microbiota composition. Knowing the importance of the microbiome in the regulation of bone density, we investigated the effect of postantibiotic treatment on gut and bone health. Intestinal microbiome repopulation at 4-weeks postantibiotic treatment resulted in an increase in the Firmicutes:Bacteroidetes ratio, increased intestinal permeability, and notably reduced femoral trabecular bone volume (approximately 30%, p < 0.01). Treatment with a mucus supplement (a high-molecular-weight polymer, MDY-1001 [MDY]) prevented the postantibiotic-induced barrier break as well as bone loss, indicating a mechanistic link between increased intestinal permeability and bone loss. A link between the microbiome composition and bone density was demonstrated by supplementing the mice with probiotic bacteria. Specifically, Lactobacillus reuteri, but not Lactobacillus rhamnosus GG or nonpathogenic Escherichia coli, reduced the postantibiotic elevation of the Firmicutes:Bacteroidetes ratio and prevented femoral and vertebral trabecular bone loss. Consistent with causing bone loss, postantibiotic-induced dysbiosis decreased osteoblast and increased osteoclast activities, changes that were prevented by both L. reuteri and MDY. These data underscore the importance of microbial dysbiosis in the regulation of intestinal permeability and bone health, as well as identify L. reuteri and MDY as novel therapies for preventing these adverse effects. © 2018 American Society for Bone and Mineral Research.

ACTIVITY OF AMPICILLIN IN VITRO COMPARED WITH OTHER ANTIBIOTICS

Comparative tests in vitro for antibacterial activity were carried out with ampicillin, tetracycline, and chloramphenicol using 673 clinical isolates of Gram-negative bacilli and Streptococcus faecalis. Further comparative tests were also carried out with ampicillin, chloramphenicol, colistin sulphate, colistin methane sulphonate, cycloserine, kanamycin, nitrofurantoin, polymyxin, streptomycin, and tetracycline, using groups of 20 strains of each of the main species selected at random from the total number of isolates. Of the total number of isolates a higher percentage was inhibited by ampicillin than by tetracycline or chloramphenicol. Ampicillin showed particularly high activity against certain species of bacteria and displayed an antibacterial spectrum not shown by any of the other antibiotics tested.

MUTATIONS TO PENICILLIN RESISTANCE IN THE ENTEROBACTERIACEAE THAT AFFECT SENSITIVITY TO SERUM AND VIRULENCE FOR THE MOUSE

Roantree, Robert J. (Stanford University School of Medicine, Stanford, Calif.), and John P. Steward. Mutations to penicillin resistance in the Enterobacteriaceae that affect sensitivity to serum and virulence for the mouse. J. Bacteriol 89:630-639. 1965.-Series of mutants resistant to benzylpenicillin or alpha-aminobenzylpenicillin were derived from serum-resistant strains of Escherichia coli and Salmonella by the gradientplate technique. Serum-sensitive mutants were detected in series derived from 16 of the 19 strains used, and these retained the parental O type. Most series were characterized by a mutational step to a high degree of sensitivity to serum. Penicillin-resistant mutants of virulent S. typhimurium and S. enteritidis were less virulent than the parent strains; those which were very sensitive to serum usually showed the greatest loss of virulence. One class of mutants from S. enteritidis was sensitive to human serum but virulent for mice. We found that the mice lack bactericidal antibody against this strain and that immunization with it leads to a high degree of protection.